SYNTHESIS AND BIOLOGICAL EVALUATION OF (E)-3-(2-(4-SUBSTITUTEDPHENYL)-1H-INDOLE-3-YL)-(4-SUBSTITUTEDPHENYL) PROP-2-EN-1-ONE AS ANTI-INFLAMMATORY AGENTS by Dillivaraprasad E et al.
Dillivaraprasad E et al. IRJP 2012, 3 (12) 
Page 128 
  INTERNATIONAL RESEARCH JOURNAL OF PHARMACY                                                
www.irjponline.com  ISSN 2230 – 8407 
  Research Article 
   
SYNTHESIS AND BIOLOGICAL EVALUATION OF (E)-3-(2-(4-SUBSTITUTEDPHENYL)-1H-INDOLE-3-YL)-(4-
SUBSTITUTEDPHENYL) PROP-2-EN-1-ONE AS ANTI-INFLAMMATORY AGENTS 
Dillivaraprasad E*, Mastan M, Sobha Rani T, Siddalingesh M.Banakar, Venkatareddy G 
Dravidian university, Kuppam-517425, Andhra Pradesh, India 
 
Article Received on: 09/10/12 Revised on: 21/11/12 Approved for publication: 01/12/12 
 
*Email: dilliprasad861@gmail.com 
 
ABSTRACT 
The  reaction  of  2-aryl-1H-indole-3-carboxaldehydes  with  substituted  acetophenones  in  ethylene  glycol  and  piperidine  as  a  base  gives  the  (E)-3-(2-(4-
substitutedphenyl)-1H-indol-3-yl)-(4-substitutedphenyl) prop-2-en-1-one [4a-4f] in 60-70% yield after column purification. The purity of the compounds was 
checked by TLC in ethylacetate: hexane (3:7). The structures of the all the compounds were established by 
1H – NMR, LCMS analysis. The synthesized 
compounds (4a-4f) were evaluated for their anti-inflammatory activity.  
Key words: Anti-inflammatory activity, Indole derivatives, chalcones. 
 
INTRODUCTION 
Chalcones  are  well  known  intermediates  for  synthesizing 
various  heterocyclic  compounds.  The  compounds  with  the 
backbone of chalcones have been reported to possess various 
biological  activities  such  as  antimicrobial
1,  2,  3  anti-
inflammatory
4, antimalarial
5,6, antileishmanial
7, antioxidant
8, 
antitubercular
9,10,The presence of a reactive α,β-unsaturated 
keto function in chalcones was found to be responsible for 
their  anti-inflammatory  activity.  In  the  present  work  we 
report the reaction of various substituted acetophenone with 
different  substituted  aromatic  aldehyde  to  form  chalcones 
(4a-4f).  
Chalcones are α,β-unsaturated  ketone containing the reactive  
ketoethylenic  group  –CO-CH=CH-.  These  are  coloured 
compounds  because  of  the  Presence  of  the  chromophore -
CO-CH=CH-,  which  depends  in  the  presence  of  other 
auxochromes.  Different  methods  are  available  for  the 
preparation of chalcones.The most convenient method is the 
claisen-Schimdt  condensation  of  equimolar  quantities  of 
arylmethylketone  with  aryl  aldehyde  in  the  presence  of 
alcoholic alkali. 
Indoles  are  one  of  the  most  important  nitrogen  containing 
heterocyclic  molecules,  found  extensively  in  biological 
system which play vital role in biochemical process. Indole 
alkaloids  have  been  proved  to  be  medicinally  important 
natural  compounds.  Indole  ring  constitutes  an  important 
template  for  drug  design  such  as  the  classical  NSAIDs 
indomethacin and indoxole. The substitution of heterocyclic 
moiety at the 2- position of Indole ring markedly influences 
the  anti-inflammatory  activity.  A  literature  survey  reveals 
that  very  few  references  are  available  on  the  synthesis  of 
chalcones associated with indole compounds. 
Considering  the  above  observations  and  in  connection  to 
previous  publications  involving  the  synthesis  of  new 
biologically active heterocycles. I hope to report here in the 
synthesis of new series of chalcones incorporating an extra 
heterocyclic ring such as indole to screen in vivo for their 
anti-inflammatory activity and acute toxicity studies. 
 
 
 
 
 
MATERIALS AND METHODS 
Animals 
The  anti-inflammatory  activity  of  newly  synthesized 
compounds  [4a-4f]  was  carried  out  on  Albino  Wistar rats, 
Male  (100-150  g).  These  animals  were  reared  with  robust 
health by providing standard pellet diet and water ad libitum 
in the animal house under standard environmental conditions 
of temperature, relative humidity, and 12 h dark/light cycle. 
After randomization into various groups and before initiation 
of experiment, the rats were acclimatized for one week. The 
animal  experiments  were  previously  approved  by 
Institutional Ethical Committee (IEC) and followed CPCSEA 
requirements.  
Materials 
The chemicals and solvents were purchased from commercial 
suppliers  either  from  Aldrich,  Spectrochem  and  they  were 
used  without  purification  prior  to  use.  The  melting  points 
were determined in open capillary electronic apparatus. The 
1H NMR were recorded in DMSO-d6 using NMR Bruker 300 
MHz spectrometer and chemical shifts are reported as parts 
per  million  (ppm)  using  tetramethylsilane  (TMS)  as  an 
internal standard and analyzed by mass spectra using Agilent. 
To  monitor  the  reactions  and  to  establish  the  identity  and 
purity of reactants and products, thin layer chromatography 
(TLC) was performed on pre-coated plastic sheets of silica 
gel  using  different  solvent  systems  and  the  spots  were 
visualized by exposure to iodine, KmnO4 and UV chamber.  
Carrageenan,  Formaldehyde  solution,  Dimethylformamide, 
Tragacanth  and  all  chemicals  used  in  this  study  were 
laboratory  grade.  Indomethacin  used  as  a  standard  drug 
purchased form Research Lab fine Chem Industries. 
Scheme of Synthesis 
The synthesis of the title compounds [4a-4f] is outlined in 
Figure  1.  The  required  intermediate-2  was  prepared  by 
following  vilsmeier-haack  conditions;  intermediate-3  was 
prepared  by  following  Suzuki  conditions.  The  obtained 
aldehyde  compound  (intermediate-3)  further  treated  with 
different Para substituted acetophenones to obtain chalcones 
(4a-4f)  by  following  Clasein-Schimdt  reaction  in  60-70% 
yield after column purification. The purity of the compounds 
was  checked  by  TLC  in  ethylacetate:  hexane  (3:7).  The 
structures of the all the compounds were established by 
1H-
NMR, LCMS. 
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Figure 1: Scheme of synthesis for (E)-3-(2-(4-substitutedphenyl)-1H-indol-3-yl)-(4-substitutedphenyl) prop-2-en-1-one (4a-4f) 
i) DMF, POBr3, DCM, 45
OC, 1h ii) PdCl2 (dppf), Na2CO3, 1, 4-dioxane: H2O (5:1), 95
OC, 5h iii) Piperidine, Ethylene glycol, 160
OC, 6h 
 
Synthesis of 2-bromo-1h-indole-3-carbaldehyde (2) 
To  a  solution  of  dimethylformamide  (0.68  mmol)  in 
dichloromethane (10 mL) was added drop wise a solution of 
phosphorus oxybromide (22.5 mmol) in dichloromethane (10 
mL) at 0
oC. The white thick mixture was refluxed during 20 
min, and then oxindole (7.5 mmol) was added portion wise. 
The mixture was stirred at reflux during 1h. Reaction was 
monitored  by  TLC.  After  completed  the  reaction,  reaction 
mixture  was  quenched  by  addition  of  crushed  ice  to  the 
media. The mixture was stirred for 30 min, and then layers 
were separated. The aqueous layer was neutralized with solid 
potassium  carbonate.  The  pale  yellow  precipitate  which 
appeared was washed with cold water, solid material taken in 
dichloromethane  dried  over  Na2SO4  and  concentrated 
completely. After concentration of solvent pale yellow solid 
(1.34 g, 80%) was obtained.  
2-Bromo-1H-indole-3-carbaldehyde (compound 2)  
1H NMR (DMSO-d6): δ 7.2- 8.0 (m, 4 H, Ar), 9.88 (s, 1H, 
CHO), 12.48 (brs, 1H, NH) MS: [M+2] m/z 226 
Synthesis  of  2-(4-hydroxy-phenyl)-1h-indole-3-
carbaldehyde (3)  
The  mixture  of  compound-2  (4.46  mmol),  phenyl  boronic 
acid (4.9 mmol), Pd (dppf) Cl2 (0.0002 mmol), Na2CO3 (8.9 
mmol)  in  dioxane:  H2O  (5:1)  was  heated  to  90
oC  under 
nitrogen atmosphere for 5h.Reaction was monitored by TLC. 
When  reaction  was  completed  the  mixture  was  filtered 
through  celite  pad,  washed  with  ethyl  acetate,  layers  were 
separated.  Organic  layer  was  dried  over  Na2SO4, 
concentrated under reduced pressure. Crude compound was 
purified  by  column  chromatography  to  obtained  (0.74  g, 
70%) as a brown color solid. 
 2-(4-Hydroxy-phenyl)-1H-indole-3-carbaldehyde 
(compound 3) 
1HNMR (DMSO-d6):δ 6.99-8.10 (m, 8H, Ar),12.2 (brs, 
1H,NH),10.04(s,1H,CHO),9.9(S,1H,OH) MS:[M+H] m/z 
238 
General procedure for synthesis of (e)-3-(2-(4-substituted 
phenyl)-1h-indole-3-yl)-(4-substituted  phenyl)  prop-2-en-
1-one (4a-4f) 
Indole-3-carbaldehyde  (4.2  mmol),  4-  substituted 
acetophenone  (8.4  mmol)  and  piperidine  (8.4  mmol)  were 
mixed into 10 mL ethylene glycol. The solution was refluxed 
at 150-160
0C for 5-6 h. The solution was cooled; diluted with 
water  and  extracted  with  ethylacetate.  Organic  layer  was 
dried over Na2SO4 and concentrated and crude was purified 
by  column  chromatography  to  obtained  (1.33  g,  68%, 
compound 4a) as a solid.  
The  spectral  analysis  of  the  synthesized  compounds  is  as 
follows: 
(E)-3-[2-(4-Hydroxy-phenyl)-1H-indol-3-yl]-1-(4-iodo-
phenyl)-prop-2-en-1-one (compound 4a) 
1H NMR (DMSO-d6): δ 7.59-7.64 (d, J=15.6Hz, 1H, =CH-
Ar), 6.99-8.1 (m, 12H, Ar), 8.06 (d, J=15.9 Hz, 1H-COCH=), 
12.2 (brs, 1H, NH), 10.01(s, 1H, OH) MS: [M+H] m/z 466 
(E)-  3-[2-(4-hydroxy-phenyl)-1H-indol-3-yl]-1-(4-Chloro-
phenyl) - prop-2-en-1-one (compound 4b) 
1H NMR (DMSO-d6): δ 7.46-7.48 (d, J=15Hz, 1H, =CH-Ar), 
6.99-8.1  (m,  12H,  Ar),  8.07  (d,  J=15.6Hz,  1H-COCH=), 
12.13  (brs,  1H,  NH),  10.02(s,  1H,  OH)  MS:  [M+H]  m/z 
374.6 
(E)-3-[2-(4-Hydroxy-phenyl)-1H-indol-3-yl]-1-(4-
trifluoromethyl-phenyl)-prop-2-en-1-one (compound 4c) 
1H NMR (DMSO-d6): δ 7.63-7.68 (d, J=15 Hz, 1H, =CH-Ar), 
6.99-8.1  (m,  12H,  Ar),  8.09  (d,  J=15.3  Hz,  1H-COCH=), 
12.18 (brs, 1H, NH), 10.02(s, 1H, OH) MS: [M+H] m/z 408 
(E)-3-[2-(4-Hydroxy-phenyl)-1H-indol-3-yl]-1-p-tolyl- 
prop-2-en-1-one (compound 4d) 
1H NMR (DMSO-d6): δ 7.64-7.69 (d, J=15 Hz, 1H, =CH-Ar), 
6.99-8.1  (m,  12H,  Ar),  8.09  (d,  J=15.3  Hz,  1H-COCH=), 
12.07 (brs, 1H, NH), 9.99(s, 1H, OH), 2.45 (S, CH3) MS: 
[M+H] m/z 354 
(E)- 3-[2-(4-hydroxy-phenyl)-1H-indol-3-yl]-1-(4-Fluoro 
phenyl) - prop-2-en-1-one (compound 4e) 
1H NMR (DMSO-d6): δ 7.63-7.68 (d, J=15 Hz, 1H, =CH-Ar), 
6.99-8.1  (m,  12H,  Ar),  8.06  (d,  J=15.3  Hz,  1H-COCH=), 
12.11 (brs, 1H, NH), 10.02 (s, 1H, OH) MS: [M+H] m/z 358 
(E)-3-[2-(4-Hydroxy-phenyl)-1H-indol-3-yl]-1-(4-nitro-
phenyl) - prop-2-en-1-one (compound 4f) 
1H NMR (DMSO-d6): δ 7.71-7.76 (d, J=15 Hz, 1H, =CH-Ar), 
6.99-8.1 (m, 12H, Ar), 8.18 (d, J=15.3 Hz, 1H-COCH=), 12.3 
(brs, 1H, NH), 10.1 (s, 1H, OH) MS: [M+H] m/z 385 
 
 
Table 1: Physical data of the newly synthesized (E)-3-(2-(4-substitutedphenyl)-1H-indol-3-yl)-(4-substitutedphenyl) prop-2-en-1-one (4a-4f) 
Compound  R1  Molecular Weight  MP (
0C)  Yield (%)  Rf values 
4a  I  465.29  135-137  68  0.60 
4b  Cl  373.84  140-142  67  0.56 
4c  CF3  407.40  120-122  68  0.45 
4d  CH3  353.42  130-132  65  0.50 
4e  F  357.4  118-120  60  0.45 
4f  NO2  384.4  125-127  62  0.58 Dillivaraprasad E et al. IRJP 2012, 3 (12) 
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Biological screening for synthesized compounds (4a-4f) 
Animal experimentation 
Test substance:  
The test compounds titled as 4a, 4b, 4c, 4d, 4e and 4f were 
screened for the anti-inflammatory activity in rats at the dose 
of 10 mg/kg. All the standard drug and test compounds were 
dissolved in 0.1% DMF and further made it into suspension 
by using 1% Tragacanth in water. 
Carrageenan induced paw edema model in rats
11:  
Wistar rats were fasted over night and randomly allotted to 
nine groups where n=5. Group I and II served as normal and 
disease  control  which receives  vehicle  alone.  Group  III  to 
VIII administered with the test substances 4a, 4b, 4c, 4d, 4e 
and 4f respectively (10 mg/kg b.w.) and Group IX treated 
with indomethacin (10 mg/kg b.w.) p.o.. 0.1 ml of 1% w/v 
suspension of carrageenan was injected into the sub-plantar 
region  of  the  right  hind  paw  of  each  rat  30  mins  post 
treatment with drug. The paw volume (in mL) was measured 
by using a digital plethysmometer, at different time intervals 
viz. 0, 30, 60,120, 180 and 240 min.  
Formalin induced paw edema model in rats
12:  
Overnight fasted Wistar rats were randomly divided into nine 
groups of five animals each. Group I served as normal and 
Group II disease control and received vehicle, Group III to 
VIII received the test substances 4a, 4b, 4c, 4d, 4e and 4f 
respectively  (10  mg/kg  b.w.)  and  Group  IX  received 
Indomethacin (10 mg/kg b.w.) via oral route. 30 mins Post 
treatment of drugs, 0.1 ml of 10% v/v solution of formalin 
was injected into the sub-plantar region of the right hind paw 
of  each  rat.    The  paw  volume  was  measured 
plethysmographically  using  a  digital  plethysmometer  at 
several time points as fallows 0, 30, 60, 120, 180 and 240 
min. 
Statistical analysis of the data was performed using One way 
ANOVA followed by Tukeys’s multiple comparison tests. 
 
 
Table 2: Effect of Test compounds 4a, 4b, 4c, 4d, 4e, and 4f on Carrageenan induced paw edema 
Paw Volume(mL) after  different time interval  (Time in minutes) 
Groups  0  30  60  120  180  240 
Normal  0.91 ± 0.04  1.03 ± 0.05
b  0.98 ± 0.03
c  1.01 ± 0.06
 c  1.03 ± 0.05
 c  1.02 ± 0.06
 c 
Carrageenan (1%, 0.1 ml)  1.02 ± 0.01  1.33 ± 0.01  1.46 ± 0.03  1.64 ± 0.06  1.76 ± 0.10  1.97 ± 0.15 
4a (10 mg/Kg)  0.92 ± 0.03  1.15 ± 0.06  1.23 ± 0.07
a  1.34 ± 0.06
a  1.43 ± 0.08
a  1.53 ± 0.08
b 
4b (10 mg/Kg)  0.93 ± 0.03  1.03 ± 0.02
 b  1.17 ± 0.03
 c  1.35 ± 0.07
a  1.44 ± 0.03
b  1.44 ± 0.05
b 
4c (10 mg/Kg)  0.95 ± 0.04  1.26 ± 0.07  1.23 ± 0.02
a  1.35 ± 0.02
a  1.55 ± 0.02  1.60 ± 0.08 
4d (10 mg/Kg)  0.92 ± 0.04  1.24 ± 0.04  1.27 ± 0.02
a  1.45 ± 0.01  1.43 ± 0.01
a  1.41 ± 0.01
c 
4e (10 mg/Kg)  0.94 ± 0.06  1.30 ± 0.03  1.36 ± 0.02  1.32 ± 0.33
a  1.56 ± 0.06
b  1.49 ± 0.06
b 
4f (10 mg/Kg)  1.05 ± 0.03  1.23 ± 0.06  1.38 ± 0.03  1.42 ± 0.05  1.48 ± 0.05
a  1.50 ± 0.07
a 
Indomethacin (10 mg/Kg)  0.96 ± 0.03  1.21 ± 0.06  1.34 ± 0.06  1.27 ± 0.06
b  1.27 ± 0.06
c  1.32 ± 0.06
c 
Values are expressed in MEAN±SEM. n=5. ANOVA followed by Tukeys multiple comparison tests. Values are stastically 
ap<0.05, 
bp<0.01, and
 cp<0.001 
when compared with carrageenan control. 
 
Table 3: Effect of compounds 4a, 4b, 4c, 4d, 4e, and 4f on formalin induced paw edema 
Treatment 
(Dose mg/kg. p.o.) 
Paw Volume, ml after  different time interval (Time in minutes) 
0  30  60  120  180  240 
Normal  1.02 ± 0.01  1.05 ± 0.02
c  1.07 ± 0.02
 c  1.13 ± 0.01
 c  1.08 ± 0.02
 c  1.07 ± 0.01
 c 
Formalin (10%, 0.1 ml)  1.03 ± 0.01  1.42 ± 0.03  1.66 ± 0.03  1.77 ± 0.02  2.13 ± 0.18  1.97 ± 0.03 
4a (10 mg/Kg)  1.05 ± 0.02  1.24 ± 0.02  1.63 ± 0.08  1.69 ± 0.07  1.70 ± 0.08
 a  1.77 ± 0.06
 a 
4b (10 mg/Kg)  1.07 ± 0.07  1.34 ± 0.02  1.46 ± 0.04  1.45 ± 0.02  1.60 ± 0.03
 b  1.64 ± 0.02
 c 
4c (10 mg/Kg)  0.95 ± 0.04  1.45 ± 0.01  1.52 ± 0.03  1.64 ± 0.04
 b  1.69 ± 0.03
 a  1.66 ± 0.01
 c 
4d (10 mg/Kg)  1.05 ± 0.01  1.36 ± 0.01  1.45 ± 0.01  1.50 ± 0.02
 b  1.68 ± 0.03
 b  1.60 ± 0.03
 c 
4e (10 mg/Kg)  1.04 ± 0.06  1.33 ± 0.11  1.48 ± 0.07  1.64 ± 0.08  1.66 ± 0.06
 b  1.73 ± 0.06
 b 
4f (10 mg/Kg)  1.15 ± 0.06  1.50 ± 0.03  1.54 ± 0.02  1.63 ± 0.03  1.67 ± 0.01
 b  1.70 ± 0.02
 c 
Indomethacin (10 mg/Kg)  0.95 ± 0.03  1.34 ± 0.06  1.38 ± 0.04
 b  1.44 ± 0.03
 c  1.47 ± 0.02
 c  1.46 ± 0.01
 c 
Values are expressed in MEAN±SEM. n=5. 
ap<0.05, 
bp<0.01, and
 cp<0.001 when compared with Formalin Control. 
     
RESULTS AND DISCUSSION 
Significant  induction  of  paw  inflammation  observed  in 
carrageenan control (1%, 0.1 ml and 
bp<0.01 
cp<0.001) with 
increased paw volume in the all the time interval as compared 
to  normal  control.  Treatment  4b  at  the  dose  of  10  mg/kg 
significantly
  (
ap<0.005
bp<0.001
cp<0.001)  inhibited  the 
carrageenan induced paw edema at 30, 60, 120, 180 and 240 
min  interval  as  compared  to  carrageenan  control. 
Administration of 4a and 4c significantly reduced paw edema 
at 60, 120 and 240 min interval as compared to carrageenan 
control. Where as in   4d 4e, 4f treatment, the inhibition of 
carrageenan induced paw edema was found to significant at 
120, 180 and 240 min interval. Treatment with standard drug 
indomethacin significantly inhibited the carrageenan induced 
paw edema at 120, 180 and 240 min intervals Table 2.    
Administration  of  formalin  (10%,  0.1  ml)  significantly 
(
cp<0.001)  increased  the  paw  volume  in  the  all  the  time 
interval as compared to normal control. Oral administration 
of  4a,4b,4c,4d,4e  and  4f    in  the  dose  of  10  mg/kg 
significantly
  (
bp<0.001
cp<0.001  inhibited  the  formalin 
induced paw edema at 180 and 240 min interval as compared  
 
to formalin control. Whereas in treatment with standard drug 
indomethacin significantly (
bp<0.001
cp<0.001) inhibited the 
formalin induced paw edema at 60, 120, 180 and 240 min 
interval Table 3.    
The  purpose  of  the  present  study  was  to  examine  whether 
molecular modification of Indole and Isoxazole would result 
in molecules with good anti-inflammation actions. A series of 
compounds  was  synthesized  and  evaluated  for  biological 
activities.  In  this  study,  synthesis  and  pharmacological 
screening  of  various  derivatives  of  (E)-3-(2-(4-
substitutedphenyl)-1H-indol-3-yl)-(4-substitutedphenyl) 
prop-2-en-1-one. These compounds to be testing in vivo for 
their anti-inflammatory activities. The results showed that the 
incorporation  of  appropriately  substituted  phenyl  ring  in 
Indole  nucleus  can  afford  good  anti-inflammation  actions. 
α,β-unsaturated  carbonyl  group  having  substituted  phenyl 
ring  were  in  general  more  active  than  unsubstituted  ones, 
indicating  that  the  presence  of  functional  group  may  be 
helpful  in  orienting  the  molecule  in  active  site.  The 
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functional groups at 4
th position of the phenyl ring showed 
good activity than other substitutions. 
       
CONCLUSION 
A  new  series  of  (E)-3-(2-(4-substitutedphenyl)-1H-indol-3-
yl)-(4-substitutedphenyl)  prop-2-en-1-one  [4a-4f]  were 
synthesized  for  anti-inflammatory  activity.  The  test 
compounds  4b  and  4e  have  significant  anti-inflammatory 
activity  against  carrageenan induced  paw  edema.  Chalcone 
derivatives contain α,β-unsaturated carbonyl moiety which is 
responsible  for  anti-inflammatory  activity.  Synthesized 
chalcone  derivatives  were  subjected  to  anti-inflammatory 
screening using the carrageenan-induced rat hind paw edema 
model. Chalcone derivatives at dose 10 mg/kg by oral route 
inhibited significantly the formation of edema. The P value 
was found to be <0.05 showing significant anti-inflammatory 
activity. The compound ‘4-fluoro/4-chloro chalcone’ showed 
more activity comparable to standard drug indomethacin due 
to -F/-Cl groups present in the compound. Hence, the anti-
inflammatory activity of chalcone derivatives was increased 
when electron withdrawing groups (EWG) were present on 
the chalcone moiety. 
The  results  indicated  that  these  compounds  have  potential 
effect  against  acute  as  well  as  chronic  inflammatory 
conditions.  The  compound  4c  has  acute  anti  inflammatory 
activity,  whereas  4a,  4d,  and  4f  have  also  shown  anti-
inflammatory activity, indicates these compounds are active 
against chronic inflammatory conditions. 
Further the detailed structural activity relationship studies are 
required along with the molecular manipulation i.e. molecular 
modeling may give better drugs. Molecules prepared for the 
biological  testing  do  not  always  turn  out  as  potential  new 
drugs. 
 
 
 
REFERENCES 
1.Y.Rajendra  prasad,  A. Lakshmana Rao and  R.  Rambabu, Synthesis and 
Antimicrobial Activity of Some Chalcone Derivatives, E.J. Chem., 2008 ,5 
(3), 461-466. 
2.  Silvia  N.  López,  María  V.  Castelli,  Susana  A.  Zacchino,  José  N. 
Domínguez, Gricela Lobo, Jaime Charris-Charris, Juan C. G. Cortés, Juan C. 
Ribas,  Cristina  Devia,  Ana  M.  Rodríguez,  Ricardo  D.  Enriz,  In  vitro 
antifungal evaluation and structure-activity relationships of a new series of 
chalcone  derivatives  and  synthetic  analogues,  with  inhibitory  properties 
against polymers of the fungal cell wall, Bioorg. Med.Chem. 2001, 9, 1999-
2013. 
3. Bhagyesh Baviskar, Sureshbhi Patel, Bhushan Baviskar, S.S. Khadabadi, 
Mahendra  Shiradkar,  Design  and  Synthesis  of  Some  Novel  Chalcones  as 
Potent Antimicrobial Agent, Asian J. Res. Chem., 2008,1(2),67-69. 
4. Felipe Herencia, M. Luisa Ferrandiz, Amalia Ubeda, Jose N. Domínguez, 
Jaime  E.  Charris,  Gricela  M.  Lobo,  M.  Jose  Alcaraz,  Synthesis  and  anti-
inflammatory  activity  of  chalcone  derivatives,  Bioorg.  Med.  Chem.  Lett., 
1998, 8, 1169-1174. 
5.  Xiang  Wu,  Prapon  Wilairat,  Mei-Lin  Go,  Antimalarial  Activity  of 
Ferrocenyl Chalcones, Bioorg. Med. Chem. Lett. 2002, 12(17), 2299-2302. 
6.Anu  Agarwal,  Kumkum  Srivastava,  S.K.  Puri,  Prem  M.S. 
Chauhan,Synthesis of 4-pyrido-6-aryl-2- substituted amino pyrimidines as a 
new class of antimalarial agents, Bioorg. Med. Chem., 2005, 13, 6226-6232. 
7.  Todigoppula  Narender,  Tanvir  Khaliq,  Shweta,  Nishi,  Neena  Goyal, 
Suman Gupta. Synthesis of chrominochalcone and evaluation of their in vitro 
antileishmanial activity, Bioorg. Med. Chem., 2005, 13, 6543-6550. 
8.  Jen-Hao  Cheng,  Chi-Feng  Hung,  Shyh-Chyun  Yang,  Jih-Pyang  Wang, 
Shen-Jeu  Won,  Chun-NanLin,  Synthesis  And  Cytotoxic,  Anti-
Inflammatory,And Anti-Oxidant Activities of 2 ,5 -Dialkoxylchalcones As 
Cancer Chemopreventive Agents,Bioorg. Med. Chem., 2008, 16(15), 7270-
7276. 
9.Yuh-Meei Lin, Yasheen Zhou, Michael T. Flavin,Li-Ming Zhou, Weiguo 
Nie,  Fa-Ching  Chen,Chalcones  and  flavonoids  as  anti-Tuberculosis 
agents,Bioorg. Med. Chem., 2002, 10, 2795-2802. 
10.  P.M.  Sivakumar,  S.  Prabu  Seenivasan,  VanajaKumar,  Mukesh  Doble, 
Synthesis,  antimycobacterialactivity  evaluation,  and  QSAR  studies  of 
chalconederivatives 
Bioorg. Med. Chem. Lett., 2007, 17, 1695-1700. 
11. Sharma S, Lakshmi KS, patidar A, Chaudhary A, Dhaker S. Studies on 
anti-inflammatory  effect  of  aqueous  extract  of  leaves  of  Holoptelea 
integrifolia, Planch. In rats. Indian J Phramacol 2009; 41(2):87-8. 
12.  Vogel  WH,  Scholkens  BA,  Sandow  J,  Muller  G,  Vogel  WF.    Drug 
discovery  and  evaluation.2nd  Ed.    New  York:    Springer-Verlag  Berlin 
Heidelberg; 2002.697, 759-760. 
 
 
 
 
 
Source of support: Nil, Conflict of interest: None Declared 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IRJP is an official publication of Moksha Publishing House. Website:  www.mokshaph.com. All rights reserved.  
 